Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer

Liu, Qingyun; Yu, Zhengping; Yuan, Shuai; Xie, Wenting; Li, Chengying; Hu, Zhangxue; Xiang, Ying; Wu, Na; Wu, Long; Li, Bai; Li, Yafei

doi:10.18632/oncotarget.14369

Cited by 225 publications

(162 citation statements)

References 67 publications

Supporting

Mentioning

155

Contrasting

Unclassified

Order By: Relevance

“…Elevated levels of exosomal miR-23b-3p, miR-10b-5p and miR-21-5p were independently associated with poor OS [with hazard ratio of 2.42 (1.45-4.04), P=0.001; 2.22 (1.18-4.16), P=0.013; 2.12 (1.28-3.49), P=0.003, respectively]. When compared to a model derived from clinical prognostic variables, adding the three exosomal miRNA signatures significantly improved survival predictive accuracy with an increase of timedependent area under the receiver operating characteristic curve from 0.88 to 0.91 (P=0.015) (26).…”

Section: Micrornas (Mirs)mentioning

confidence: 94%

“…Moreover, RNA, including miRs are much more stable when isolated and stored together with exosomes, providing higher yield. In a recent study (26), with a quantitative polymerase chain reaction (qPCR) array panel, 84 plasma exosomal miR samples were analyzed from 10 patients with NSCLC and 10 healthy controls. Elevated levels of exosomal miR-23b-3p, miR-10b-5p and miR-21-5p were independently associated with poor OS [with hazard ratio of 2.42 (1.45-4.04), P=0.001; 2.22 (1.18-4.16), P=0.013; 2.12 (1.28-3.49), P=0.003, respectively].…”

Section: Micrornas (Mirs)mentioning

confidence: 99%

See 1 more Smart Citation

Blood-based biomarkers in lung cancer: prognosis and treatment decisions

Xu‐Welliver¹,

Carbone²

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Despite recent advances, non-small cell lung cancer (NSCLC) remains a devastating disease with overall poor prognosis. Major contributing factors include obstacles to diagnosing the disease early in its course during the asymptomatic stage as well as diversity and complexity of its biology underlying tumorigenesis and tumor progression. Advances in molecularly targeted therapies which drives the development of personalized cancer care require precise and comprehensive understanding of tumor biology, not only at the time of diagnosis but also during treatment course and surveillance. As lung tumor tissue can be difficult to obtain without invasive and potentially risky procedures, it is difficult to monitor treatment response with serial tissue biopsies. Development of non-invasive but reliable blood based tumor markers has become an important research area. In this review, we focus on the following circulating biomarkers that have been identified in recent years: circulating tumor cells (CTCs); circulating cell-free nucleic acids, such as circulating tumor DNA (ctDNA) and microRNA (miR); and other biomarkers such as genomic and proteomic features. These biomarkers not only have prognostic values, but also can help guild treatment decisions by monitoring tumor burden, detecting minimal residual disease and/or recurrent disease, as well as monitoring evolution of genetic alterations throughout the treatment course.

show abstract

Section: Micrornas (Mirs)mentioning

confidence: 94%

Section: Micrornas (Mirs)mentioning

confidence: 99%

Blood-based biomarkers in lung cancer: prognosis and treatment decisions

Xu‐Welliver¹,

Carbone²

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

show abstract

“…Recently, exosomal transport of miRNAs has gained attention as a carrier of genetic information [18]. Regarding NSCLC patients, only a few papers have reported on the usefulness of exosomal miRNA as a prognostic biomarker [19][20][21]. It was shown that miR-146a-5p levels in serum exosomes predict progression-free survival of NSCLC patients [19].…”

Section: Introductionmentioning

confidence: 99%

“…It was shown that miR-146a-5p levels in serum exosomes predict progression-free survival of NSCLC patients [19]. Another study reported that elevated levels of plasma exosomal miR-23b-3p, miR-10b-5p, and miR-21-5p were prognostic biomarkers for NSCLC patients [20]. Our group also demonstrated that miR-21 and miR-4257 levels of plasma exosomes are useful biomarkers for diseasefree survival (DFS) of NSCLC patients [21].…”

Section: Introductionmentioning

confidence: 99%

Usefulness of Plasma Exosomal MicroRNA-451a as a Noninvasive Biomarker for Early Prediction of Recurrence and Prognosis of Non-Small Cell Lung Cancer

et al. 2018

View full text Add to dashboard Cite

Objectives: The aim of this study was to clarify the usefulness of plasma exosomal microRNA-451a (miR-451a) as a novel biomarker for the early prediction of recurrence and prognosis in non-small cell lung cancer (NSCLC) patients after curative resection. Methods: Before surgery, plasma samples were collected and exosomal microRNA (miRNA) levels were evaluated. We first profiled specific exosomal miRNAs related to recurrence in 6 NSCLC patients with stage IA cancer by miRNA microarray. We then validated the usefulness of selected miRNAs as biomarkers using the other 285 NSCLC patients. Results: Plasma exosomal miR-451a showed the highest upregulation in the NSCLC patients with recurrence in the miRNA microarray analysis. A significant positive correlation was demonstrated between exosomal miR-451a levels and NSCLC tissue miR-451a levels. Exosomal miR-451a showed a significant association with lymph node metastasis, vascular invasion, and stage. In stage I, II, or III patients, the overall survival (OS) and disease-free survival (DFS) rates among the high-exosomal-miR-451a patients were significantly worse than those among the low-exosomal-miR-451a patients. In Cox multivariate analysis, exosomal miR-451a showed significance for OS and DFS. Conclusion: Plasma exosomal miR-451a might serve as a reliable biomarker for the prediction of recurrence and prognosis in NSCLC patients with stage I, II, or III cancer.

show abstract

“…Liu and colleagues used a quantitative polymerase chain reaction (qPCR) array panel to analyze 84 plasma exosomal miRNAs in 10 lung adenocarcinoma patients and 10 matched healthy controls. The results showed that increased levels of exosomal miR-23b-3p, miR-10b-5p and miR-21-5p were independently related to poor overall survival [27]. Rabinowits et al evaluated the expression levels of specific exosomal miRNAs in patients with and without lung adenocarcinoma and they though circulating exosomal miRNA might be useful as an acceptable marker for diagnosis and prognosis in patients with lung cancer [28].…”

Section: Exosomal Mirnas As Diagnostic and Predictive Biomarkers In Lmentioning

confidence: 99%

The functional role of exosome microRNAs in lung cancer

Gong

Zhu

et al. 2017

Open Life Sciences

View full text Add to dashboard Cite

Lung cancer causes the highest incidence and mortality rates of cancer disease worldwide. Despite obvious advances in lung cancer research, a better understanding of the disease is urgently needed to improve early detection and correct diagnoses. Exosomes are released from cancer cells and modulate cell-cell communication. Exosomes transfer a wide variety of molecules including microRNAs. MicroRNAs (miRNAs) are single-stranded, small noncoding RNAs that regulate gene expression. Accumulating evidence indicates that miRNA expression patterns represent the status of physiology and disease. The focus of this review is to provide an update on the progress of miRNAs of cancer-derived exosome as potential biomarkers for lung cancer.

show abstract

Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer

Cited by 225 publications

References 67 publications

Blood-based biomarkers in lung cancer: prognosis and treatment decisions

Blood-based biomarkers in lung cancer: prognosis and treatment decisions

Usefulness of Plasma Exosomal MicroRNA-451a as a Noninvasive Biomarker for Early Prediction of Recurrence and Prognosis of Non-Small Cell Lung Cancer

The functional role of exosome microRNAs in lung cancer

Contact Info

Product

Resources

About